Subtype
Astrocytic Tumor
CI-CAN-00001839Explore in graph →
Non-malignant507 active trials2 approved drugs67 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001839Explore in graph →
Clinical trials
1,861 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | terminated | Phase 2 | 43 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00107003 | GW572016 to Treat Recurrent Malignant Brain Tumors | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00335764 |
| Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
| completed |
| Phase 1 / Phase 2 |
| 92 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jul 2, 2018 |
| clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT02157103 | A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma | completed | Phase 2 | 3 | Emory UniversityOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT01602588 | A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)(HCQ) | completed | Phase 2 | 54 | University College, LondonOTHER | 1 | May 3, 2018 | clinicaltrials |
| NCT01860638 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | completed | Phase 2 | 296 | Hoffmann-La RocheINDUSTRY | 15 | Apr 30, 2018 | clinicaltrials |
| NCT02227576 | Prevention of Thrombocytopenia in Glioblastoma Patients(PLATUM) | terminated | Phase 2 | 20 | University Hospital, LilleOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02945826 | uPAR-PET/MRI in Glioblastoma Multiforme | unknown | Phase 2 | 35 | Rigshospitalet, DenmarkOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT00003456 | Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00003471 | Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma | terminated | Phase 2 | 7 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00003474 | Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme | completed | Phase 2 | 40 | Burzynski Research InstituteOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT02654041 | Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients | terminated | Phase 2 | 3 | Musli Thyropeutics Ltd.INDUSTRY | 1 | Mar 22, 2018 | clinicaltrials |
| NCT00200161 | Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma | completed | Phase 2 | 127 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01788280 | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT01632228 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | completed | Phase 2 | 135 | Hoffmann-La RocheINDUSTRY | 8 | Feb 5, 2018 | clinicaltrials |
| NCT02047214 | Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy | terminated | Phase 2 | 17 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT03388372 | Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma | completed | Phase 2 | 39 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT00895180 | Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 80 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 27, 2017 | clinicaltrials |
| NCT01753713 | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 33 | Manmeet Ahluwalia, MDOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2017 | clinicaltrials |
| NCT03294486 | Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients(ONCOVIRAC) | unknown | Phase 1 / Phase 2 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01666600 | NOA-12: BIBF1120 and R-RT in Glioblastoma | terminated | Phase 1 / Phase 2 | 63 | Prof. Dr. Wolfgang WickOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT01866449 | Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme | completed | Phase 2 | 24 | University of UlmOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2017 | clinicaltrials |
| NCT03310372 | Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme(TEMOFRAC) | completed | Phase 2 | 46 | Central Hospital, Nancy, FranceOTHER | 0 | Oct 17, 2017 | clinicaltrials |
| NCT01759810 | Proteome-based Personalized Immunotherapy of Glioblastoma | unknown | Phase 2 / Phase 3 | 60 | NeuroVita ClinicOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT01310868 | Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma | completed | Phase 2 | 59 | University College, LondonOTHER | 1 | Oct 5, 2017 | clinicaltrials |
| NCT01508117 | Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | terminated | Phase 2 | 1 | University of CincinnatiOTHER | 1 | Sep 19, 2017 | clinicaltrials |
| NCT00187486 | Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors | completed | Phase 2 | 66 | University of California, San FranciscoOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT00003470 | Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma(AA) | completed | Phase 2 | 27 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT02029573 | Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma(ART) | completed | Phase 2 | 36 | King Fahad Medical CityOTHER_GOV | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00980343 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00540722 | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2017 | clinicaltrials |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 59 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT03212235 | Hypofractionated Radiation Therapy for Glioblastoma | unknown | Phase 2 | 58 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00823797 | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | completed | Phase 2 | 45 | University of WashingtonOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT01290263 | Amgen 386 for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | withdrawn | Phase 2 | 0 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT00112866 | Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme | terminated | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00392171 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | completed | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00684567 | Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) | completed | Phase 2 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT01310855 | Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 38 | University College, LondonOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00345163 | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)(BRAIN) | completed | Phase 2 | 167 | Genentech, Inc.INDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT00783393 | SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) | completed | Phase 2 | 32 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT01122901 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jul 20, 2018source: clinicaltrials